x

Posted 04 January, 2024

Trustfeed Corp. appointed new CEO

CEO Change detected for ticker OTC:TRFE in a 8-K filed on 04 January, 2024.


  In accordance with the SPA and the transactions contemplated thereby, effective as of the Closing Date, (a) Rasmus Refer, the Company's Chief Executive Officer (principal executive officer, principal accounting officer and principal financial officer) and Chairman and sole member of the Company's Board of Directors, resigned from all officer and employment positions with the Company and its subsidiaries, and (b) subject to Rule 14f-1 of the Securities Exchange Act of 1934, as amended, Mr. Refer resigned as a director of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Trustfeed Corp.
Health Care/Life Sciences • Medical Equipment/Supplies
Trustfeed Corp. engages in the research and development of portable organ transport devices. Its product reconditions the donor organ such as the heart, kidney, or liver. The company was founded on September 14, 2000 and is headquartered in New York, NY.
Market Cap
$26.7M
View Company Details
Trustfeed Corp. by TradingView
Relevant filing section
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers.


In accordance with the SPA and the transactions contemplated thereby, effective as of the Closing Date, (a) Rasmus Refer, the Company's Chief Executive Officer (principal executive officer, principal accounting officer and principal financial officer) and Chairman and sole member of the Company's Board of Directors, resigned from all officer and employment positions with the Company and its subsidiaries, and (b) subject to Rule 14f-1 of the Securities Exchange Act of 1934, as amended, Mr. Refer resigned as a director of the Company. Mr. Refer did not have any disagreements with the Company regarding the operations, policies or practices of the Company.


Also in accordance with the SPA and the transactions contemplated thereby, effective as of the Closing Date, (a) the size of the Board of Directors of the Company was increased from one director to two directors and Brett Rosen was appointed as a director to fill the vacancy, to serve as director until the next annual meeting of stockholders of the Company, subject to his prior resignation or removal, and until his successor is duly elected and qualified and (b) Mr. Rosen was appointed President, Chief Financial Officer, Secretary and Treasurer of the Company.


As of the Closing Date, the Company will not pay Mr. Rosen any compensation for his service to the Company. There are no related party transactions between the Company and Mr. Rosen that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, except that to the extent that affiliates of GLD Partners, LP directly or indirectly own any interest in the Company through CWR or otherwise, Mr. Rosen may have an indirect ownership interest in the Company through his equity participation rights and interests in affiliates of GLD Partners, LP.


Mr. Rosen, age 41, is the President and a director of GLD RE, Ltd., an affiliate of GLD Partners, LP, a global alternative investment management firm ("GLD Partners, LP"), since March 2022, and is the President of CWR since April 2021. From April 2018 to March 2022, Mr. Rosen was Legal Counsel at GLD Partners, LP. Prior to that, from July 2012 to March 2018, he was associated with Winston & Strawn, LLP, the global law firm. The Company believes that Mr. Rosen is qualified to serve as a member of the Board of Directors due to his extensive business and legal experience, including experience from acting as a director of various portfolio companies of GLD Partners, LP.


2